Allergan et al. v. Sun Pharmaceutical Industries, Inc.
Infringement action filed 29 Oct 2020 in the United States District Court for the District of Delaware and closed 12 Oct 2023, with US7741356B2 asserted. Recorded basis of termination: case consolidated.
Case record
- Patent involved
- US7741356B2
- Application no.
- US11/079647
- Case no.
- 1:20-cv-01479
- Verdict cause
- Infringement action
- Court
- D. Del.
- Court level
- District Court
- Case region
- Delaware
- Chief judge
- Richard G. Andrews
- Trial level
- First instance
- Filed – Closed
- 29 Oct 2020 – 12 Oct 2023
- Duration
- 1078 days
- Basis of termination
- Case Consolidated
- Products & marks
- ANDA No. 213447 seeks FDA approval for the commercial manufacture, use, and sale of generic oral tablet products containing 75 mg and 100 mg of eluxadoline as the active ingredient
- Validity challenges
- None recorded
Check this patent against your own product
Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.
Get an FTO claim chart- 01Ranked prior artEvery hit source-linked
- 02Claim-level comparisonAgainst your own product
- 03Legal statusAcross 174 jurisdictions
Compounds as opioid receptor modulators
The present invention is directed to novel opioid receptor modulators of Formula (I).The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
- Legal status
- Active
- Granted
- 22 Jun 2010
- Earliest priority
- 15 Mar 2004
- Est. expiry
- 27 May 2029
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- BRESLIN, HENRY J. · CAI, CHAOZHONG · HE, WEI · KAVASH, ROBERT W.
- Classification
- A61K31/4174A61K31/4178C07D233/64A61K31/4172A61K31/454C07D233/54
- Prosecution counsel
- COVINGTON & BURLING, LLP
- Examiner
- SHIAO, REI-TSANG
Parties of record
Allergan
- Core tech
- Not recorded
- Counsel
- Jack B. Blumenfeld · Jeremy A. Tigan
- Firm
- Morris, Nichols, Arsht & Tunnell LLP
- Also named
- Janssen Pharmaceutica, N.V. · Allergan Holdings Unlimited Company · Allergan Pharmaceuticals International Limited
Sun Pharmaceutical Industries, Inc.
- Core tech
- Not recorded
- Counsel
- Charles B. Klein · Dominick T. Gattuso · Gregory J. Winter · Jovial Wong · Kevin J. Boyle · Zachary B. Cohen
- Firm
- Heyman Enerio Gattuso & Hirzel, LLP
Counsel of record
| Attorney | For | Role |
|---|---|---|
| Jack B. Blumenfeld | Allergan | Plaintiff |
| Jeremy A. Tigan | Allergan | Plaintiff |
| Charles B. Klein | Sun Pharmaceutical Industries, Inc. | Defendant |
| Dominick T. Gattuso | Sun Pharmaceutical Industries, Inc. | Defendant |
| Gregory J. Winter | Sun Pharmaceutical Industries, Inc. | Defendant |
| Jovial Wong | Sun Pharmaceutical Industries, Inc. | Defendant |
| Kevin J. Boyle | Sun Pharmaceutical Industries, Inc. | Defendant |
| Zachary B. Cohen | Sun Pharmaceutical Industries, Inc. | Defendant |
Basis of termination
From the record · verbatim“WHEREAS, the action against Sun Pharmaceutical Industries Limited under the docket number 20-1479 is related to C.A. No. 19-1727, which is currently pending before this Court; IT IS HEREBY STIPULATED by the parties, subject to the approval of the Court, that: 1. C.A. No. 20-1479 (RGA) shall be consolidated with C.A. No. 19-1727 (RGA) for all purposes; 2. All filings shall be made in the lead case C.A. No. 19-1727 (RGA); Case 1:20-cv-01479-RGA Document 60 Filed 07/12/22 Page 1 of 2 PageID #: 376 2 3. All deadlines in the Scheduling Order in the lead case C.A. No. 19-1727 (RGA) (D.I. No. 14, as modified by D.I. Nos. 81, 156, 208, 226, 303, 333, and 340) shall remain in effect as to both C.A. Nos. 19-1727 and 20-1479.”
Case 1:20-cv-01479 · D. Del. · closed 12 October 2023
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
Frequently asked questions
What is case 1:20-cv-01479?
1:20-cv-01479 is a patent infringement action brought by Allergan against Sun Pharmaceutical Industries, Inc., filed on 29 Oct 2020 in the United States District Court for the District of Delaware. The case closed on 12 October 2023.
Which patent was asserted in 1:20-cv-01479?
US7741356B2 (“Compounds as opioid receptor modulators”), assigned to JANSSEN PHARMACEUTICA, N. V., currently active. The record also lists ANDA No. 213447 seeks FDA approval for the commercial manufacture, use, and sale of generic oral tablet products containing 75 mg and 100 mg of eluxadoline as the active ingredient.
How was case 1:20-cv-01479 terminated?
The recorded basis of termination is case consolidated. The termination text reads: “WHEREAS, the action against Sun Pharmaceutical Industries Limited under the docket number 20-1479 is related to C.A. No. 19-1727, which is currently pending before this Court; IT IS HEREBY STIPULATED by the parties, subject to the approval of the Court, that: 1. C.A. No. 20-1479 (RGA) shall be consolidated with C.A. No. 19-1727 (RGA) for all purposes; 2. All filings shall be made in the lead case C.A. No. 19-1727 (RGA); Case 1:20-cv-01479-RGA Document 60 Filed 07/12/22 Page 1 of 2 PageID #: 376 2 3. All deadlines in the Scheduling Order in the lead case C.A. No. 19-1727 (RGA) (D.I. No. 14, as
How long did case 1:20-cv-01479 take?
1078 calendar days, from filing on 29 Oct 2020 to closure on 12 October 2023.
Who were the attorneys and the judge in 1:20-cv-01479?
Chief Judge Richard G. Andrews presided. Jack B. Blumenfeld and Jeremy A. Tigan are recorded as counsel for plaintiff Allergan. Charles B. Klein, Dominick T. Gattuso, Gregory J. Winter, Jovial Wong, Kevin J. Boyle and Zachary B. Cohen appear for defendant Sun Pharmaceutical Industries.
Disclaimer. This page reproduces publicly available court docket data for case 1:20-cv-01479 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.